Background The aim of this study is to evaluate the impact of diabetes, hypertension,
cardiovascular disease and the use of angiotensin converting enzyme inhibitors/angiotensin …

Aim The novel coronavirus infection (COVID-19), now a worldwide public health concern is
associated with varied fatality. Patients with chronic underlying conditions like diabetes and …

Background and aims COVID-19 is already a pandemic. Emerging data suggest an
increased association and a heightened mortality in patients of COVID-19 with …

Background Many studies on COVID-19 have reported diabetes to be associated with
severe disease and mortality, however, the data is conflicting. The objectives of this meta …

Background and aims Currently there is limited knowledge on medical comorbidities and
COVID-19; we conducted a systematic review and meta-analysis to evaluate the impact of …

Background Currently, the number of patients with SARS-COV-2 infection has increased
rapidly in Iran, but the risk and mortality of SARS-COV-2 infection in Iranian patients with …

Background The novel coronavirus disease 2019 (COVID-19) has spread worldwide since
the beginning of 2020, placing the heavy burden on the health systems all over the world …

Abstract Background and Aims; To investigate the association between use of angiotensin-
converting enzyme inhibitor (ACEI)/angiotensin-receptor blocker (ARB) and outcomes of …

Background and aims This meta-analysis aims to highlight the impact of cardio-metabolic
comorbidities on COVID-19 severity and mortality. Methods A thorough search on major …

Background Diabetes mellitus (DM) and cardiovascular disease (CVD) are present in a
large number of patients with novel Coronavirus disease 2019 (COVID-19). We aimed to …